NDLI: Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.

Please wait, while we are loading the content...

The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.

Donepezil-induced myoclonus in a patient with Alzheimer disease.

Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.

Risk of QT/QTc prolongation among newer non-SSRI antidepressants.

Efficacy and safety of tranexamic acid versus Ïµ-aminocaproic acid in cardiovascular surgery.

Transient central diabetes insipidus induced by ketamine infusion.

Potentially inappropriate prescribing and vulnerability and hospitalization in older community-dwelling patients.

Use of nonsteroidal anti-inflammatory drugs in colorectal surgery: do the risks cast a shadow on the benefits?

Comparative persistence on ß-blockers versus calcium channel blockers for ventricular rate control in nonelderly patients with atrial fibrillation.

Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children.

Year: 2014 Volume: 48 Issue: 11

Year: 2014 Volume: 48 Issue: 10

Year: 2014 Volume: 48 Issue: 6

Year: 2014 Volume: 48 Issue: 5

Year: 2014 Volume: 48 Issue: 4

Year: 2014 Volume: 48 Issue: 3

Year: 2014 Volume: 48 Issue: 2

Year: 2014 Volume: 48 Issue: 1

Year: 2013 Volume: 47

Year: 2012 Volume: 46

Year: 2011 Volume: 45

Year: 2010 Volume: 44

Year: 2009 Volume: 43

Year: 2008 Volume: 42

Year: 2007 Volume: 41

Year: 2003 Volume: 37

Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Johnsa, Jessica D. Neville, Michael W.
Description	Country affiliation: United States Author Affiliation: Johnsa JD ( University of Georgia College of Pharmacy, Athens, GA, USA.); Neville MW ( University of Georgia College of Pharmacy, Athens, GA, USA neville@uga.edu.)
Abstract	OBJECTIVE: To examine the efficacy of tasimelteon for the treatment of non-24-hour sleep-wake disorder using evidence from controlled clinical trials. DATA SOURCES: Citations in Google Scholar and PubMed from January 1, 2008, to May 31, 2014, were identified using tasimelteon as the search term. STUDY SELECTION AND DATA EXTRACTION: Results were limited to human trials published in English. Trials that compared tasimelteon with placebo were included. DATA SYNTHESIS: A phase II trial (n = 39) evaluated the effects of tasimelteon versus placebo on improvements in sleep efficiency and the ability to shift circadian rhythms over 3 days. Significant shifts in circadian rhythm were only observed for 100-mg tasimelteon. A phase III trial (n = 412) evaluated the effects of tasimelteon versus placebo on assessment of latency to persistent sleep and wake after sleep onset; significant advantages were observed in tasimelteon recipients. The SET (Safety and Efficacy of Tasimelteon) trial (n = 84) enrolled blind men and women with Non-24. They received placebo or tasimelteon 20 mg daily. Tasimelteon recipients had significantly (P = 0.0025) better entrainment and N24CRS scores. The RESET (Randomized Withdrawal Study of the Efficacy and Safety of Tasimelteon) trial (n = 20) enrolled entrained participants from the SET trial who received 20 mg of tasimelteon or placebo daily for 8 weeks. The primary objective was to evaluate the maintenance of effect of tasimelteon to entrain circadian rhythms. Tasimelteon was associated with significantly (P = 0.0055) greater entrainment than placebo. CONCLUSION: Tasimelteon improves sleep initiation and maintenance in patients with Non-24 who have a shift in endogenous circadian rhythms. However, the cost of this agent limits its use.
File Format	HTM / HTML
ISSN	10600280
Issue Number	12
Volume Number	48
e-ISSN	15426270
Journal	Annals of Pharmacotherapy
Language	English
Publisher	SAGE Publications
Publisher Date	2014-12-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmaceutical Science Benzofurans Therapeutic Use Cyclopropanes Receptors, Melatonin Agonists Sleep Initiation And Maintenance Disorders Drug Therapy Circadian Rhythm Clinical Trials, Phase Ii As Topic Clinical Trials, Phase Iii As Topic Humans Randomized Controlled Trials As Topic Sleep Drug Effects Physiopathology Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.

Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.

Tasimelteon for insomnia.

Non-24-Hour Sleep–Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management

Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

Workshop report. Circadian rhythm sleep–wake disorders: gaps and opportunities

Melatonin agonists and insomnia.

Let there be sleep--on time.

Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.

Similar Documents

Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.

Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.

Tasimelteon for insomnia.

Non-24-Hour Sleep–Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management

Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

Workshop report. Circadian rhythm sleep–wake disorders: gaps and opportunities

Melatonin agonists and insomnia.

Let there be sleep--on time.

Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.